Verminderte Steuereinnahmen bei einer Mehrwertsteuersenkung für Humanmedikamente

This procedure is a written question concerning the potential loss of tax revenue if the Value Added Tax (VAT) rate were lowered for medications intended for human use. It seeks to clarify the fiscal consequences of making medicine more affordable through tax breaks. This primarily affects the national budget and the healthcare sector, specifically concerning the pricing and accessibility of pharmaceutical products for patients.